about
A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients.A novel approach to analyze gene expression data demonstrates that the DeltaF508 mutation in CFTR downregulates the antigen presentation pathway.Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNAGene expression profiles characterize inflammation stages in the acute lung injury in miceAbnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinaseEffect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency.Lipid mapping of colonic mucosa by cluster TOF-SIMS imaging and multivariate analysis in cftr knockout mice.Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis.Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation.Dyslipidemia in racially admixtured children with cystic fibrosisVAMP-associated Proteins (VAP) as Receptors That Couple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Proteostasis with Lipid Homeostasis.Therapeutic and Prophylactic Potential of Morama (Tylosema esculentum): A Review.Inflammation and its genesis in cystic fibrosis.Linoleic acid supplement in cystic fibrosis: friend or foe?Correction of lung inflammation in a F508del CFTR murine cystic fibrosis model by the sphingosine-1-phosphate lyase inhibitor LX2931.Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.
P2860
Q33515286-37068EBC-4650-442E-BF1A-50F2E2563C65Q33521562-05D2BDE2-AE06-480D-BD49-D4AFE6647B0AQ33603047-B6675706-AF9D-48B1-8A7E-C2027B5886F7Q33632236-ECDF3355-DC21-43FC-AF5D-99A3533F47BCQ33825143-18F6865E-6EFF-4690-9BA2-86A2F2B654FFQ33863162-5358BEA1-0785-46EE-AC40-84947E4D9DC2Q34116335-F36BA9EB-9B02-4767-9662-C2473165FB6DQ34358489-D0A43F7F-CEF3-4657-9852-7AFA00104DA1Q34813994-D99E6736-F5FA-46CE-B0C5-85DA338036F8Q35683608-BCF28EC4-F3EE-4676-ACD8-44DF2363A97FQ36107801-BB9274E7-2234-4A5B-9299-C55A322ED466Q36650360-CC9478D5-1BD5-4ADF-A8FE-BA7AD1FDDC4FQ38553294-E72A8DFF-4467-4B5E-95F3-3FEF273EDE10Q38579962-350E3472-24DF-44AD-BB3E-9D7C7B818677Q42365367-DBDC0985-1A0D-4AEB-A656-CDE2492B7A79Q48678102-6EEBCC23-B776-4361-B85E-AF35854AFEEAQ51736940-0609758D-520E-42E6-AEC8-41132FC202AF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipid metabolism in cystic fibrosis.
@en
Lipid metabolism in cystic fibrosis.
@nl
type
label
Lipid metabolism in cystic fibrosis.
@en
Lipid metabolism in cystic fibrosis.
@nl
prefLabel
Lipid metabolism in cystic fibrosis.
@en
Lipid metabolism in cystic fibrosis.
@nl
P1476
Lipid metabolism in cystic fibrosis.
@en
P2093
Tilla S Worgall
P304
P356
10.1097/MCO.0B013E32832595B7
P577
2009-03-01T00:00:00Z